I
I

IDEXX

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. STOCKS Manchester United, Verona Pharma, 89Bio

BUZZ-U.S. STOCKS ON THE MOVE-Manchester United, Verona Pharma, 89Bio Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq led the rally among Wall Street's main indexes as major rate-sensitive technology and growth stocks advanced after the Federal Reserve hinted it was close to pausing interest rate hikes amid turbulence in the banking sector.
A
A
B
C
F
I
J
N
N
R
S
T
L
R
U
U
D
F
G
M

U.S. STOCKS Ollie, Commercial Metals, Copper Aluminum miners

BUZZ-U.S. STOCKS ON THE MOVE-Ollie, Commercial Metals, Copper Aluminum miners Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes climbed on Thursday as major rate-sensitive technology and growth stocks advanced after the Federal Reserve hinted it was close to pausing interest rate hikes amid turbulence in the banking sector.
A
A
B
I
J
N
N
R
S
T
L
R
U
U
D
F
G
M

U.S. STOCKS Fat Brands, Spotify, Uber Tech

BUZZ-U.S. STOCKS ON THE MOVE-Fat Brands, Spotify, Uber Tech Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes edged lower on Monday as investors awaited Federal Reserve Chair Jerome Powell's speech for clues on when the central bank would start cutting interest rates.
A
I
N
P
S
T
O
U
U
C
D
E
L
L
S

U.S. STOCKS Apple, PayPal, Pinterest

BUZZ-U.S. STOCKS ON THE MOVE-Apple, PayPal, Pinterest Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock indexes edged lower on Monday with Tyson Foods falling on disappointing quarterly results, while investors reassessed their predictions on when the U.S.
A
I
N
P
S
T
O
U
U
C
D
E
L
L

Idexx Laboratories Announces Q4 2022 Results

BRIEF-Idexx Laboratories Announces Q4 2022 Results Feb 6 (Reuters) - Idexx Laboratories Inc IDXX.O : IDEXX LABORATORIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 RESULTS ESTIMATES 2023 EPS OF $9.27- $9.75 PROVIDES INITIAL OUTLOOK FOR 2023 REVENUE OF $3,590 MILLION - $3,690 MILLION, REFLECTING REPORTED GROWTH OF 6.5% - 9.5% FY2023 EARNINGS PER SHA
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.